MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.785 -0.215 (-2.39%)
Streaming Delayed Price Updated: 11:55 AM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call
NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performan... 
Via StockStory
Topics Earnings
News headline image
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% ye... 
Via StockStory
NeoGenomics Inc (NASDAQ:NEO) Crushes Estimates on Robust Clinical Growth, Launches Novel MRD Test ↗
Via Chartmill
News headline image
NeoGenomics (NEO) Q1 2026 Earnings Transcript ↗
NeoGenomics (NEO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
NeoGenomics (NEO) Q1 2025 Earnings Transcript ↗
NeoGenomics (NEO) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 11.1% yea... 
Via StockStory
News headline image
NeoGenomics Reports First Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics NEO Q2 2025 Earnings Transcript ↗
NeoGenomics NEO Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Retirement
News headline image
NeoGenomics Earnings: What To Look For From NEO
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday after market close. Here’s what investors should know. ... 
Via StockStory
News headline image
Why NeoGenomics (NEO) Stock Is Trading Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 4.1% in the afternoon session after the company announced that... 
Via StockStory
Topics Artificial Intelligence
News headline image
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
From NeoGenomics, Inc.
Via Business Wire
News headline image
2 Healthcare Stocks Worth Your Attention and 1 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl... 
Via StockStory
News headline image
NeoGenomics (NEO) Q4 2024 Earnings Transcript ↗
NeoGenomics (NEO) Q4 2024 Earnings Transcript 
Via The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
3 Unprofitable Stocks Walking a Fine Line
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding... 
Via StockStory
News headline image
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Let’s dig into the relative performance of NeoGenomics (NASDAQ:NEO) and its peers as we unravel the now-completed Q4 testing & diagnostics services earnings ... 
Via StockStory
News headline image
3 Cash-Burning Stocks We Think Twice About
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh... 
Via StockStory
Topics Economy
News headline image
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Reasons to Avoid NEO and 1 Stock to Buy Instead
What a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have... 
Via StockStory
News headline image
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
From NeoGenomics, Inc.
Via Business Wire
News headline image
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call
NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s... 
Via StockStory
Topics Earnings
News headline image
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a... 
Via StockStory
Topics Artificial Intelligence
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company... 
Via StockStory
News headline image
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript ↗
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story